Skip to main content

The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11–13, 2015

This is a preview of subscription content, access via your institution.

Abbreviations

ACT:

Adoptive cell transfer

ALL:

Acute lymphoblastic leukemia

CAR:

Chimeric antigen receptor

CIMT:

Association for Cancer Immunotherapy

CLL:

Chronic lymphocytic leukemia

CSF-1R:

Colony stimulating factor 1 receptor

CTL:

Cytotoxic T lymphocytes

CTLA-4:

Cytotoxic T-lymphocyte-associated protein 4

CTx:

Chemotherapy

DC:

Dendritic cells

EMA:

European Medicines Agency

EORTC:

European Organization for Research and Treatment of Cancer

FDA:

Food and Drug Administration

GM-CSF:

Granulocyte macrophage colony-stimulation factor

HLA:

Human leukocyte antigen

HMGB-1:

High-mobility group box-1

HNPCC:

Hereditary nonpolyposis colorectal cancer

HPV:

Human papilloma virus

HSCT:

Hematopoietic stem cell transplantation

IDH1:

Isocitrate dehydrogenase 1

IFN:

Interferon

IHC:

Immuno-histochemistry

IL:

Interleukin

iNOS:

Inducible nitric oxide synthetase

mAb:

Monoclonal antibody

MDACC:

MD Anderson Cancer Center

MDSC:

Myeloid-derived suppressor cells

MEK:

MAP kinase kinase

MHC:

Major histocompatibility complex

MMP-2:

Matrix metalloproteinase-2

MMR:

Mismatch repair

MSI:

Microsatellite instability

mTEC:

Medullary thymic epithelial cells

NGS:

Next-generation sequencing

NHL:

Non-Hodgkin lymphoma

OS:

Overall survival

OVA:

Ovalbumin

PBMC:

Peripheral blood mononuclear cells

PCR:

Polymerase chain reaction

PD-1:

Programmed death-1

PDAC:

Pancreatic ductal adenocarcinoma

PFS:

Progression-free survival

RIP:

Rat insulin promoter

RNA:

Ribonucleic acid

SLP:

Synthetic long peptide

TAM:

Tumor-associated macrophages

TCGA:

The Cancer Genome Atlas

TCR:

T cell receptor

Teff :

Effector T cell

TGF:

Transforming growth factor

TIL:

Tumor-infiltrating lymphocytes

TLR:

Toll-like receptor

TNF:

Tumor-necrosis factor

Treg :

Regulatory T cells

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matthias Miller.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest. Björn-Philipp Kloke has been co-organizer of the CIMT Endeavour workshop.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Miller, M., Jahndel, V., Kutscher, S. et al. The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11–13, 2015. Cancer Immunol Immunother 65, 1277–1287 (2016). https://doi.org/10.1007/s00262-016-1850-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-016-1850-5

Keywords

  • CIMT 2015
  • Cancer immunotherapy
  • Personalized immunotherapy
  • Combination therapy